Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)POLARISNCT07795658
China CRSwNP Registry Study
An observational study of Chronic Rhinosinusitis With Nasal Polyps (CRSwNP), run by Beijing Tongren Hospital at 1 site in China.
Trial summary
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a long-lasting inflammatory disease of the nose and sinuses that can cause nasal blockage, loss of smell, nasal discharge, facial discomfort, sleep problems, and reduced quality of life. Read more about this study
- Who is it for?
- Ages 12 years and older
- Conditions the study is for
- Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
- What is being tested?
- Routine Clinical Care for CRSwNP
- How many people
- 1,000 participants
- Where
- 1 siteChina
- Study dates
- 31 Oct 2026to 31 Dec 2030
- How long will I take part?
- 36 Months
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: The study population will comprise adolescents and adults aged 12 years or older with bilateral chronic rhinosinusitis with nasal polyps (CRSwNP) receiving routine clinical care at participating otolaryngology centers in China. Eligible participants will be enrolled prospectively and followed for 36 months. All treatment decisions, including medical therapy, endoscopic sinus surgery, and biologic therapy, will be made by treating physicians according to routine clinical practice and will not be assigned by the study.
Who may be able to join
- Aged 12 years or older at the time of signing the informed consent or assent form.
- Confirmed diagnosis of chronic rhinosinusitis with bilateral nasal polyps (CRSwNP) according to the Chinese Guideline for Diagnosis and Treatment of Chronic Rhinosinusitis (2024).
- Baseline Nasal Polyp Score (NPS) of at least 4 on a scale of 0 to 8, with a score of at least 1 in each nasal cavity.
- At baseline, a self-reported Nasal Congestion Score (NCS) of at least 2 and/or Loss of Smell Score (LoS) of at least 2, each assessed on a scale of 0 to 3 based on symptoms during the previous 2 weeks.
- Able and willing to comply with long-term clinical follow-up and study assessments.
- Voluntary written informed consent. For minors, written informed consent from a parent or legal guardian and participant assent will be obtained as required by applicable regulations and ethics committee requirements.
Who cannot join
- Presence of another poorly controlled serious disease, recurrent chronic disease, or infectious disease.
- Pregnancy or breastfeeding.
- History of excessive alcohol consumption, defined as more than 14 units of alcohol per week (1 unit equals 360 mL of beer, 45 mL of spirits containing 40% alcohol, or 150 mL of wine), or a history of drug abuse.
- Other concomitant conditions that may interfere with the study, including but not limited to fungal sinusitis except allergic fungal rhinosinusitis, odontogenic sinusitis, antrochoanal polyps, eosinophilic granulomatosis with polyangiitis (EGPA/Churg-Strauss syndrome), cystic fibrosis, granulomatosis with polyangiitis, Young syndrome, Kartagener syndrome, or other ciliary dyskinesia syndromes.
- Any medical, social, psychological, or personal condition that, in the investigator's judgment, may interfere with participation or reasonably be expected to prevent completion of scheduled follow-up visits and assessments, such as limited life expectancy, substance abuse, or severe cognitive impairment.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
Beijing Tongren Hospital, Capital Medical University
Beijing, Beijing Municipality, 100730
Mu Xian, MD, +86 136 7113 8761, mu_xian@126.com
About this study
Official title: POLARIS: A Prospective, Multicenter Real-World Study to Investigate the Treatment Pattern and Prognostic Outcome in Chinese Severe Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Patients
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a long-lasting inflammatory disease of the nose and sinuses that can cause nasal blockage, loss of smell, nasal discharge, facial discomfort, sleep problems, and reduced quality of life.
POLARIS is a prospective, multicenter, real-world, non-interventional registry study. It will enroll approximately 1,000 adolescents and adults aged 12 years or older with bilateral CRSwNP at about 33 centers in China and follow them for 36 months. All treatment decisions will be made by the treating physicians according to routine clinical practice. The study will not assign participants to any treatment.
The study aims to describe the disease burden, underlying inflammatory characteristics, real-world treatment patterns, effectiveness of current treatments, and long-term outcomes of Chinese patients with CRSwNP. Key assessments will include changes in nasal symptoms measured by the Total Nasal Symptom Score, changes in disease-related quality of life measured by the 22-item Sino-Nasal Outcome Test, and the proportions of patients classified as cured, controlled, or uncontrolled at months 12, 24, and 36. The study will also examine treatment escalation, surgery, systemic corticosteroid and biologic use, health care and economic burden, safety events, and clinical characteristics and biomarkers associated with persistent high disease burden or frequent treatment escalation.
Read the detailed description
This is a prospective, multicenter, real-world, non-interventional longitudinal registry study conducted at approximately 33 centers in China. Approximately 1,000 participants aged 12 years or older with bilateral chronic rhinosinusitis with nasal polyps (CRSwNP) will be followed for 36 months. Eligible participants must meet the protocol-defined diagnostic, nasal polyp score, and symptom criteria.
Participants will receive standard medical care as determined by their treating physicians. No treatment will be assigned by the study, and participation will not restrict or otherwise determine the use of medical therapy, systemic corticosteroids, biologic therapy, endoscopic sinus surgery, or other clinically indicated treatment.
The study uses a combination of scheduled and event-driven in-person visits and telephone follow-up. Scheduled in-person visits are planned at Months 3, 6, 9, 12, 18, 24, 30, and 36, and telephone visits are planned at Months 15, 21, 27, and 33.
During follow-up, participants with worsening symptoms, defined as persistent NCS of at least 2, LoS of at least 2, or SNOT-22 of at least 30 during the previous week, will have an additional in-person visit within a window of ±2 weeks to determine whether treatment escalation is needed.
Participants undergoing endoscopic sinus surgery will have an additional in-person visit approximately 2 weeks after surgery. Participants receiving a protocol-defined oral corticosteroid course of at least 7 days at a daily dose of at least 30 mg prednisone equivalent will have an additional in-person visit approximately 2 weeks after corticosteroid discontinuation. Each post-treatment visit has a window of ±2 weeks. If a participant receives two or more qualifying escalation treatments, the earliest applicable post-treatment time point will be used. Biologic initiation or switching does not trigger this additional 2-week visit.
Collected information will include demographic and clinical characteristics, medical and surgical history, comorbidities, treatment patterns, symptom scores, disease-related quality of life, nasal polyp assessments, treatment outcomes, treatment escalation events, health care resource use, economic and humanistic burden, and safety events. Laboratory results and biological specimens, including blood, nasal polyp tissue, nasal cells, and nasal secretions, may be collected as specified in the protocol and when applicable.
The primary assessments describe changes from baseline in the Total Nasal Symptom Score and the 22-item Sino-Nasal Outcome Test, and the proportions of participants classified as cured, controlled, or uncontrolled at months 12, 24, and 36. Secondary and exploratory analyses will describe treatment escalation, surgery, systemic corticosteroid and biologic use, clinical and biomarker changes, and factors associated with persistent high disease burden or frequent treatment escalation. The primary analyses will be descriptive; exploratory statistical models may be used to evaluate associations between participant characteristics, biomarkers, treatment patterns, and outcomes.
Study personnel will receive standardized protocol and data collection training. Data will be entered into an electronic data capture system with role-based access, predefined range and consistency checks, an audit trail, and investigator confirmation. Data queries, periodic monitoring, and data quality reviews will be used to address missing, inconsistent, or implausible information and to support adherence to the protocol and protection of participant privacy.
- Being tested
- Routine Clinical Care for CRSwNP
- Keywords
- CRSwNP, Severe CRSwNP, Chronic Rhinosinusitis, Nasal Polyps, Prospective Registry, Real-World Study, Treatment Patterns, Disease Burden, Treatment Escalation, Endotype, Biomarkers, Long-Term Outcomes
- Medical subject headings
- Nasal Polyps
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Routine Clinical Care for CRSwNPOther
Participants may receive any clinically indicated treatment for CRSwNP according to routine clinical practice, including intranasal corticosteroids, systemic corticosteroids, endoscopic sinus surgery, biologic therapies, and other appropriate management. Treatment selection, initiation, switching, discontinuation, and escalation are determined by the treating physicians. The study does not provide or assign any treatment; it observes real-world treatment patterns and associated clinical outcomes over 36 months.
| Study group | Role | What they receive |
|---|---|---|
| CRSwNP Registry Cohort | Approximately 1,000 adolescents and adults aged 12 years or older with bilateral chronic rhinosinusitis with nasal polyps (CRSwNP) who meet the protocol-defined nasal polyp and symptom criteria will be enrolled at approximately 33 centers in China and followed prospectively for 36 months. Participants will receive treatment selected by their treating physicians according to routine clinical practice. No treatment is assigned by the study. Receives: Other: Routine Clinical Care for CRSwNP |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline in 22-Item Sino-Nasal Outcome Test (SNOT-22) Total Score
The SNOT-22 is a 22-item patient-reported questionnaire assessing disease-related quality of life. Each item is scored from 0 to 5, giving a total score from 0 to 110, with higher scores indicating greater impairment. Change in the total score from baseline will be summarized at each specified time point.
Measured: Baseline and Months 12, 24, and 36
Change From Baseline in Total Nasal Symptom Score (TNSS)
TNSS is recorded daily by participants using a paper symptom diary. The visit-level TNSS total score and component scores will generally be derived from diary entries completed during the 14 consecutive days before each visit. Change from baseline will be summarized at each specified time point.
Measured: Baseline and Months 12, 24, and 36
Percentage of Participants in Each CRSwNP Treatment Outcome Category
At each time point, participants will be classified as cured, controlled, or uncontrolled according to protocol-defined criteria.
Cured is defined as having no rhinosinusitis-related symptoms and no mucosal edema, nasal polyps, or abnormal secretions on nasal endoscopy for 6 months without treatment intervention.
Controlled is defined as having no rhinosinusitis-related symptoms for 6 months while receiving treatment intervention, with a Nasal Polyp Score (NPS) of <=1 on each side.
Uncontrolled disease is defined as the persistence of rhinosinusitis-related symptoms despite treatment, indicated by a weekly mean Nasal Congestion Score (NCS) of at least 2 or a weekly mean Loss of Smell Score (LoS) of at least 2, or a Nasal Polyp Score (NPS) greater than 1 on either side.
The percentage of participants in each category will be summarized.
Measured: Months 12, 24, and 36
Secondary outcomes (20)
Annualized Rate of Treatment Escalation Events
The annualized rate of treatment escalation events will be calculated as the total number of events divided by the observed participant-years. Treatment escalation includes endoscopic sinus surgery or revision surgery, initiation or switching of biologic therapy for CRSwNP, and a systemic corticosteroid course of at least 7 days at a daily dose of at least 30 mg prednisone equivalent.
Measured: From baseline through Month 36
Percentage of Participants With at Least One Treatment Escalation Event
The cumulative number and percentage of participants experiencing at least one treatment escalation event will be summarized. Treatment escalation includes endoscopic sinus surgery or revision surgery, initiation or switching of biologic therapy for CRSwNP, and protocol-defined systemic corticosteroid treatment.
Measured: Months 12, 24, and 36
Time to First Treatment Escalation Event
Time from enrollment to the first treatment escalation event will be assessed. Treatment escalation includes endoscopic sinus surgery or revision surgery, initiation or switching of biologic therapy for CRSwNP, and protocol-defined systemic corticosteroid treatment.
Measured: From baseline to the first treatment escalation event, assessed through Month 36
Percentage of Participants With Controlled Disease Using Each Treatment Modality
Among participants classified as having controlled disease, the percentage using each routine-care treatment modality will be summarized. Treatment modalities include intranasal corticosteroids, oral corticosteroids, biologic therapy, and endoscopic sinus surgery.
Measured: Months 12, 24, and 36
Percentage of Participants Undergoing Endoscopic Sinus Surgery or Revision Surgery
The percentage of participants who undergo at least one endoscopic sinus surgery or revision surgery during registry follow-up will be summarized.
Measured: From baseline through Month 36
Time From Baseline to First Endoscopic Sinus Surgery or Revision Surgery
The interval from enrollment to the first endoscopic sinus surgery or revision surgery occurring during registry follow-up will be assessed.
Measured: From baseline to the first surgery, assessed through Month 36
Percentage of Participants Using Oral Corticosteroids
The percentage of participants who receive oral corticosteroid treatment at least once during registry follow-up will be summarized.
Measured: From baseline through Month 36
Annualized Number of Systemic Corticosteroid Courses per Participant-Year
The number of systemic corticosteroid courses will be divided by the observed participant-years to calculate the annualized number of courses per participant-year.
Measured: From baseline through Month 36
Cumulative Systemic Corticosteroid Dose in Prednisone Equivalents
The cumulative systemic corticosteroid dose received during registry follow-up will be calculated and expressed in milligrams of prednisone equivalent.
Measured: From baseline through Month 36
Percentage of Participants With at Least Two Systemic Corticosteroid Courses per Year
The percentage of participants receiving at least two systemic corticosteroid courses within each year of follow-up will be summarized.
Measured: Year 1, Year 2, and Year 3
Percentage of Participants Using Biologic Therapy for CRSwNP
The percentage of participants who receive at least one biologic therapy for CRSwNP during registry follow-up will be summarized.
Measured: From baseline through Month 36
Time From Enrollment to First Use of Biologic Therapy for CRSwNP
The interval from enrollment to the first use of a biologic therapy for CRSwNP will be assessed among participants initiating biologic therapy during registry follow-up.
Measured: From baseline to first biologic use, assessed through Month 36
Duration of Biologic Therapy for CRSwNP
The duration of each biologic treatment episode for CRSwNP will be summarized during registry follow-up.
Measured: From baseline through Month 36
Biologic Therapy Switching Patterns
Switching between biologic therapies for CRSwNP will be characterized, including the number and sequence of biologic therapy switches recorded during registry follow-up.
Measured: From baseline through Month 36
Biologic Therapy Discontinuation and Reasons for Discontinuation
Biologic therapy discontinuations will be summarized, including the percentage of participants discontinuing biologic therapy and the documented reasons for discontinuation.
Measured: From baseline through Month 36
Cumulative CRSwNP-Related Healthcare Resource Utilization
The cumulative numbers of CRSwNP-related outpatient visits, emergency department visits, and hospitalizations will be summarized through Months 12, 24, and 36. Healthcare resource utilization occurring both at and outside participating sites may be captured from available medical records or participant report, with the data source and verifiability recorded.
Measured: From enrollment through Months 12, 24, and 36
Cumulative CRSwNP-Related Direct Medical Costs
Cumulative available and traceable direct medical costs related to CRSwNP management, including outpatient, emergency department, and hospitalization costs, will be summarized through Months 12, 24, and 36. Costs that cannot be verified or clearly attributed to CRSwNP management will not be imputed.
Measured: From enrollment through Months 12, 24, and 36
Work Productivity and Activity Impairment Outcomes
Changes from baseline in Work Productivity and Activity Impairment Questionnaire scores, including absenteeism, presenteeism, overall work impairment, and activity impairment, will be assessed at Months 12, 24, and 36. The cumulative number of work or school days missed because of CRSwNP will also be summarized through each time point.
Measured: Baseline and Months 12, 24, and 36
Number and Percentage of Participants With Serious Adverse Events
All serious adverse events occurring during registry follow-up will be collected through continuous passive collection, irrespective of treatment or intervention type, and summarized descriptively.
Measured: From baseline through Month 36
Number and Percentage of Participants With Patient-Reported Biologic-Related Adverse Drug Reactions
Patient-reported adverse drug reactions related to biologic therapy that are documented during routine clinical care will be collected, when applicable, and summarized descriptively.
Measured: From baseline through Month 36
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Aug 2026
- Study start31 Oct 2026 (estimated)
- Primary completion31 Dec 2030 (estimated)
- Study completion31 Dec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (15)Papers the sponsor has linked to this study.
- Other trials for Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,000 participants (estimated)
- Target duration
- 36 Months
Sponsor and investigators
- Lead sponsor
- Beijing Tongren Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- AstraZeneca
- Responsible party
- Sponsor
- Investigators
- Chengshuo Wang, MD, PhD, Principal investigator, Beijing Tongren HospitalLuo Zhang, MD, PhD, Principal investigator, Capital Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07795658
- Sponsor's protocol ID
- POLARIS
- Acronym
- POLARIS
- Status last verified
- Aug 2026
- First submitted
- 26 Aug 2026
- Last updated
- 31 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Kratchmarov R, Dharia T, Buchheit K. Clinical efficacy and mechanisms of biologics for chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2025 May;155(5):1401-1410. doi: 10.1016/j.jaci.2025.03.011. Epub 2025 Mar 23.
PubMed 40132672Han JK, Silver J, Dhangar I, Veeranki P, Deb A. Quantifying corticosteroid burden in chronic rhinosinusitis with nasal polyps: A retrospective US database study. Ann Allergy Asthma Immunol. 2025 Jun;134(6):685-693.e5. doi: 10.1016/j.anai.2024.10.015. Epub 2024 Oct 19.
PubMed 39428097Zhang J, Sima Y, Shao S, Zheng M, Zhao Y, Gao F, Wang X, Zhang L. Cost-utility and clinical outcome analysis of surgery or oral corticosteroids treatment in patients with chronic rhinosinusitis with nasal polyps. Asia Pac Allergy. 2024 Dec;14(4):174-182. doi: 10.5415/apallergy.0000000000000160. Epub 2024 Oct 28.
PubMed 39624448DeConde AS, Mace JC, Levy JM, Rudmik L, Alt JA, Smith TL. Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis. Laryngoscope. 2017 Mar;127(3):550-555. doi: 10.1002/lary.26391. Epub 2016 Nov 12.
PubMed 27859303Bachert C, Bhattacharyya N, Desrosiers M, Khan AH. Burden of Disease in Chronic Rhinosinusitis with Nasal Polyps. J Asthma Allergy. 2021 Feb 11;14:127-134. doi: 10.2147/JAA.S290424. eCollection 2021.
PubMed 33603409Lou H, Meng Y, Piao Y, Wang C, Zhang L, Bachert C. Predictive significance of tissue eosinophilia for nasal polyp recurrence in the Chinese population. Am J Rhinol Allergy. 2015 Sep-Oct;29(5):350-6. doi: 10.2500/ajra.2015.29.4231. Epub 2015 Jul 27.
PubMed 26219765Guo CL, Lu RY, Wang CS, Zhao JF, Pan L, Liu HC, Liao B, Liu Z. Identification of Inflammatory Endotypes by Clinical Characteristics and Nasal Secretion Biomarkers in Chronic Rhinosinusitis with Nasal Polyps. Int Arch Allergy Immunol. 2023;184(10):955-965. doi: 10.1159/000530193. Epub 2023 May 30.
PubMed 37253337Ma L, Deng Y, Wang K, Shi J, Sun Y. Relationship between Eosinophilic and Neutrophilic Inflammation in Chinese Chronic Rhinosinusitis with Nasal Polyps. Int Arch Allergy Immunol. 2023;184(6):576-586. doi: 10.1159/000528946. Epub 2023 Feb 6.
PubMed 36746133Yu J, Xian M, Piao Y, Zhang L, Wang C. Changes in Clinical and Histological Characteristics of Nasal Polyps in Northern China over the Past 2-3 Decades. Int Arch Allergy Immunol. 2021;182(7):615-624. doi: 10.1159/000513312. Epub 2021 Feb 17.
PubMed 33596581Shi JB, Fu QL, Zhang H, Cheng L, Wang YJ, Zhu DD, Lv W, Liu SX, Li PZ, Ou CQ, Xu G. Epidemiology of chronic rhinosinusitis: results from a cross-sectional survey in seven Chinese cities. Allergy. 2015 May;70(5):533-9. doi: 10.1111/all.12577. Epub 2015 Mar 4.
PubMed 25631304Bachert C, Han JK, Wagenmann M, Hosemann W, Lee SE, Backer V, Mullol J, Gevaert P, Klimek L, Prokopakis E, Knill A, Cavaliere C, Hopkins C, Hellings P. EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management. J Allergy Clin Immunol. 2021 Jan;147(1):29-36. doi: 10.1016/j.jaci.2020.11.013. Epub 2020 Nov 20.
PubMed 33227318Xian M, Yan B, Song X, Chen J, Tang J, Jiang Y, Wan L, Liu W, Xue J, Cao Z, Yu Y, Yang X, Shi L, Wang G, Xu Y, Yang Y, Ye J, Jiang L, Quan F, Tan G, Liu F, Xu Z, Zhang X, Li J, Su L, Yang Y, Fan J, He G, Zhu L, Wang X, Wang M, Shen S, Li J, Li H, Wei X, Yu H, Liu Z, Ma R, Liu H, Liu J, Lv W, Yang Q, Zhu D, Cheng L, Wang C, Zhang L. Chinese Position Paper on Biologic Therapy for Chronic Rhinosinusitis With Nasal Polyps. Allergy. 2025 May;80(5):1208-1225. doi: 10.1111/all.16519. Epub 2025 Mar 5.
PubMed 40042059Zhu DD, Yu HM, Xian M, Song XC, Chen JJ, Tang J, Jiang Y, Wan LJ, Liu W, Xue JM, Cao ZW, Yu YF, Yang XL, Shi L, Wang GK, Xu Y, Yang YC, Ye J, Jiang LY, Quan F, Tan GL, Liu F, Xu ZD, Zhang XW, Li JP, Su LZ, Yang Y, Fan JG, He G, Zhu L, Guo R, Wang XD, Yan B, Wang M, Shen S, Yang G, Li J, Li HB, Wei X, Liu Z, Ma RX, Liu HH, Liu JF, Lyu W, Yang QT, Cheng L, Wang CS, Zhang L. [Expert consensus on the treatment of chronic rhinosinusitis with nasal polyps with biologics (2025)]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2025 Nov 7;60(11):1389-1398. doi: 10.3760/cma.j.cn115330-20250527-00295. Chinese.
PubMed 41330581Subspecialty Group of Rhinology, Editorial Board of Chinese Journal of Otorhinolaryngology Head and Neck Surgery; Subspecialty Group of Rhinology, Society of Otorhinolaryngology Head and Neck Surgery, Chinese Medical Association. Chinese Guidelines for Diagnosis and Treatment of Chronic Rhinosinusitis (2024). World J Otorhinolaryngol Head Neck Surg. 2025 Aug 14;12(1):25-55. doi: 10.1002/wjo2.70031. eCollection 2026 Feb.
PubMed 41657428Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, Toppila-Salmi S, Bernal-Sprekelsen M, Mullol J, Alobid I, Terezinha Anselmo-Lima W, Bachert C, Baroody F, von Buchwald C, Cervin A, Cohen N, Constantinidis J, De Gabory L, Desrosiers M, Diamant Z, Douglas RG, Gevaert PH, Hafner A, Harvey RJ, Joos GF, Kalogjera L, Knill A, Kocks JH, Landis BN, Limpens J, Lebeer S, Lourenco O, Meco C, Matricardi PM, O'Mahony L, Philpott CM, Ryan D, Schlosser R, Senior B, Smith TL, Teeling T, Tomazic PV, Wang DY, Wang D, Zhang L, Agius AM, Ahlstrom-Emanuelsson C, Alabri R, Albu S, Alhabash S, Aleksic A, Aloulah M, Al-Qudah M, Alsaleh S, Baban MA, Baudoin T, Balvers T, Battaglia P, Bedoya JD, Beule A, Bofares KM, Braverman I, Brozek-Madry E, Richard B, Callejas C, Carrie S, Caulley L, Chussi D, de Corso E, Coste A, El Hadi U, Elfarouk A, Eloy PH, Farrokhi S, Felisati G, Ferrari MD, Fishchuk R, Grayson W, Goncalves PM, Grdinic B, Grgic V, Hamizan AW, Heinichen JV, Husain S, Ping TI, Ivaska J, Jakimovska F, Jovancevic L, Kakande E, Kamel R, Karpischenko S, Kariyawasam HH, Kawauchi H, Kjeldsen A, Klimek L, Krzeski A, Kopacheva Barsova G, Kim SW, Lal D, Letort JJ, Lopatin A, Mahdjoubi A, Mesbahi A, Netkovski J, Nyenbue Tshipukane D, Obando-Valverde A, Okano M, Onerci M, Ong YK, Orlandi R, Otori N, Ouennoughy K, Ozkan M, Peric A, Plzak J, Prokopakis E, Prepageran N, Psaltis A, Pugin B, Raftopulos M, Rombaux P, Riechelmann H, Sahtout S, Sarafoleanu CC, Searyoh K, Rhee CS, Shi J, Shkoukani M, Shukuryan AK, Sicak M, Smyth D, Sindvongs K, Soklic Kosak T, Stjarne P, Sutikno B, Steinsvag S, Tantilipikorn P, Thanaviratananich S, Tran T, Urbancic J, Valiulius A, Vasquez de Aparicio C, Vicheva D, Virkkula PM, Vicente G, Voegels R, Wagenmann MM, Wardani RS, Welge-Lussen A, Witterick I, Wright E, Zabolotniy D, Zsolt B, Zwetsloot CP. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020 Feb 20;58(Suppl S29):1-464. doi: 10.4193/Rhin20.600.
PubMed 32077450